Axcan May Ax Itax Program For Functional Dyspepsia After Phase III Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axcan's decision on whether to abandon Itax (itopride) development for functional dyspepsia will await further analysis of a failed international Phase III trial and results of a second Phase III study due in June
You may also be interested in...
Axcan Helicide "not approvable" again
Axcan receives second "not approvable" letter for its H. pylori agent Helicide (bismuth/metronidazole/tetracycline) Oct. 3, citing ongoing manufacturing deficiencies at one of five manufacturing sites. Axcan received the first not approvable letter Aug. 12, 2002 addressing similar manufacturing-related issues. The firm said it "will meet with FDA in the coming weeks to discuss alternative plans." The Canadian firm previously projected approval before year-end (1Pharmaceutical Approvals Monthly May 1, 2003, p. 10). Helicide was approved in Canada March 14...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product